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Abstract
Background: Mycophenolic acid (MPA), a selective inhib-
itor of lymphocyte proliferation, has lately been used to
improve renal function and prolong graft survival in renal
transplanted patients. Still, there is no consensus considering
the recommended dosing and the therapeutic range of MPA.
Methods: To estimate the safe therapeutic range of MPA, its
plasma level and indicators of kidney function were meas-
ured in 216 patients (138 male, 78 female, age 46"12 years)
67"46 months after transplantation. Besides MPA, patients
received cyclosporine (Group A, ns122) or tacrolimus
(Group B, ns77). Seventeen patients (Group C) were treated
with MPA in combination with everolimus or sirolimus. Plas-
ma MPA was measured by enzyme inhibition assay.
Results: In the whole study group MPA level increased with
the dose of MPA (ps0.013). MPA level was below the ther-
apeutic range in 40% (Group A) and 45% (Group B) of
patients, respectively. MPA was 1.9"1.56 mg/L in Group A,
2.4"1.69 mg/L in Group B. In Group A MPA level
increased and cyclosporine decreased with the progress of
renal disease.
Conclusions: Increasing MPA/cyclosporine ratio at more
severe stages of chronic kidney disease was tolerable for the
patients and rejection could be avoided. Tubular damage
detected by urinary N-acetyl-b-D-glucosaminidase did not
correlate with the MPA level.
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Introduction
Mycophenolic acid (MPA) is the pharmacologically active
form of the immunosuppressant mycophenolate mofetil
(MMF). By inhibiting inosine monophosphate dehydrogen-
ase – the key enzyme in purine biosynthesis – MPA selec-
tively inhibits the proliferation of human T and B
lymphocytes, which depend on the de novo pathway for
DNA synthesis instead of the alternative salvage pathway.
According to current and experimental immunosuppressive
drug protocols in kidney transplanted patients, MPA is used
during pre- and post-adaptation maintenance, in various
combinations with calcineurin inhibitors (cyclosporine or
tacrolimus), sirolimus or prednisone (1). Insertion of MMF
into the protocols has greatly contributed to the reduction of
acute rejection (2, 3). Moreover, a recent meta-analysis found
that the minimization or even elimination of calcineurin
inhibitors in patients receiving MMF significantly improved
renal function and prolonged graft survival (4).
Recently, a new EMIT (Enzyme Multiplied Immunoassay
Test) with a strong correlation with HPLC (5–7) has been
developed for the determination of plasma mycophenolic
acid. In the liver MPA is transformed into its major glucu-
ronide metabolite (MPAG). Among minor metabolites (at
least three) acyl-glucuronide is pharmacologically active.
The method we used is only capable of measuring total MPA
concentration, it cannot distinguish between parent and
daughter compounds.
Only free MPA is responsible for immunosuppressive
activity, while protein binding can reach 99%. Therefore,
conditions causing hypoalbuminemia can alter the pharma-
codynamic effect of MPA by increasing the plasma concen-
tration of the free drug (8). In addition to significant
inter-individual variability, MPA also demonstrates time-
dependent pharmacokinetics (9) and ethnic variability. At
increasing MPA concentrations adverse effects may arise
(gastrointestinal symptoms, leukopenia, anemia) resulting
from MPA-induced inhibition of DNA synthesis and cell pro-
liferation. Former studies showed a strong correlation
between therapeutic plasma total MPA trough levels and
clinical response (10), which points out the importance of
accurate dosing.
According to the literature the personal dosage for myco-
phenolate mofetil (MMF) should be empirically determined.
MMF dosage suggested in combination with cyclosporin A
is 2 g/day, when combined with tacrolimus it is 1 g/day.
2 Ola´h et al.: Monitoring of mycophenolic acid
Article in press - uncorrected proof
Figure 1 Relationship of MPA levels with daily dose.
In the whole study group (216 patients) MPA level slightly
increased with the daily dose. Kruskal-Wallis test: ps0.013. Box
and whiskers plot; circles and asterisks label outliers.
Although therapeutic drug monitoring (TDM) is not obliga-
tory, patients often complain about side-effects of MMF
(nausea, abdominal spasm, diarrhea, leukopenia, anemia and
thrombopenia), which diminish as the dose is lowered.
The aim of this study was to investigate the relation
between the dosage and blood level of MPA at different stag-
es of chronic kidney disease (CKD). Since cyclosporine may
have nephrotoxic side-effects, we estimated the MPA/cyclo-
sporine ratio which is still safe and effective against kidney
rejection. Finally, we investigated whether these doses of
MPA-cyclosporine combination may cause tubular damage,
anemia or leukopenia.
Materials and methods
We retrospectively surveyed the data of 216 patients (138 male, 78
female, age: 46"12 years (mean"SD)), they were studied
67"46 months (mean"SD) after kidney transplantation. During
the observation period of 4 months (September 1st–December 31st
2008) no kidney rejection was registered.
Enrollment criteria
Adult patients, who were treated with MPA combined with another
immunosuppressive drug after kidney transplantation and suffered
from gastrointestinal side-effects and/or anemia (monitored since
the 3rd post-operative day) were enrolled in the study.
Exclusion criteria
The exclusion criteria were lack of compliance during treatment,
age under 18 years, pregnancy, lactation, history of hepatopathy,
severe leukopenia (total leukocyte count -2 G/L) or thrombopenia
(-50 G/L) at the time of enrollment, inability to be nurtured and
treated orally. Simultaneously added immunosuppressive drugs were
cyclosporin A (Group A, ns122), tacrolimus (Group B, ns77),
other patients (Group C) received everolimus (ns5) or sirolimus
(ns12) with MMF and prednisone. MMF (mycophenolate mofetil)
dosage was 0.5–2 g/day depending on the individual patient’s tol-
erance. The 10–15 mg/kg cyclosporin A administration was divided
into two doses. Dose was raised when cyclosporine C2 level
decreased below the therapeutic range (400–1400 mg/L).
Tacrolimus was administered orally starting from 0.1 mg/kg every
12 h, to reach the blood trough level therapeutic range of 5–15 mg/L.
Everolimus had an initial dose regimen of 0.75 mg twice a day.
Dose was adjusted after 4–5 day intervals until blood trough level
reached 3.0–8.0 mg/L.
Initial Sirolimus dose was 2 mg/day; blood trough level thera-
peutic range was 5–10 mg/L.
For drug monitoring whole blood was collected in K3EDTA
anti-coagulated Becton Dickinson vacutainer tubes (BD, UK) and,
if necessary, plasma was separated by centrifugation (15 min,
900 g). In the case of MPA sampling was performed before the
daily intake of MPA. In Group A peak level of cyclosporine was
measured 2 h after medication, if patients entered the outpatient
center at the proper time. In some cases, when patients arrived late,
the trough level of cyclosporine was checked instead, and therefore
these cases were excluded from the statistical analysis of cyclo-
sporin C2. Trough concentration (C0) of total plasma MPA was
measured by enzyme inhibition assay (EIA, Cobas Integra 800,
Roche Ltd). Tacrolimus and sirolimus were determined in K3EDTA
anti-coagulated blood samples (BD, UK) with microparticle enzyme
immunoassay (MEIA-IMx, Abbott Laboratories, USA). Cyclospo-
rine A and everolimus levels were measured in K3EDTA anti-coag-
ulated blood (BD, UK) by fluorescent polarization immunoassay
(FPIA-TDx, Abbott Laboratories, USA).
Serum samples were separated by centrifugation (15 min, 900 g)
from the blood samples collected in native BD tubes containing a
gel separator. Renal function was characterized by serum creatinine
(compensated Jaffe method for creatinine, Roche Modular P800)
and estimated glomerular filtration rate (eGFR). GFR (mL/min/
1.73 m2) were calculated by the 4v-MDRD (four-variable Modified
Diet for Renal Disease study group) formula (11–13), as the Nation-
al Kidney Education Program recommended for the IDMS cali-
brated creatinine (SCr) method:
eGFRs175ØAge–0.203Ø(SCr 0.0113)–1.154Ø(0.742 if female)Ø(1.21 if
black)
Tubular function was followed by N-acetyl-b-D-glucosaminidase
activity (NAG) measured by colorimetric enzyme assay (PPR Diag-
nostics, London, UK) from the first morning urine collected in plas-
tic native tubes (BD, UK). In order to compensate the diurnal
variance in urinary excretion, NAG activity of the first morning
urine was related to urinary creatinine (Jaffe kinetic assay, Cobas
Integra-800, Roche Ltd, Germany) and their ratio was given as uri-
nary NAG index (14, 15).
The white blood cell (WBC) count and hemoglobin levels were
measured in venous blood anti-coagulated with K3EDTA (Advia
2120, Siemens Ltd). Serum C-reactive protein was determined by
immunoturbidimetric method (Modular P800), serum procalcitonin
was measured by chemiluminescent immunoassay (Cobas e411,
Roche Ltd, Mannheim, Germany). Serum samples were separated
from the blood collected in native tube containing gel (BD, UK).
Normality of the drug levels distribution was checked by Kol-
mogorov-Smirnov test. Drug levels in different CKD stages were
compared by Kruskal-Wallis test and ANOVA.
Results
In the whole study group (216 patients) MPA levels
increased with the daily dose (Figure 1, Kruskal-Wallis test:
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Figure 2 MPA level and peak level of cyclosporine in Group A.
MPA level significantly increased (Kruskal-Wallis test: ps0.012), and peak level of cyclosporine significantly decreased (ANOVA:
ps0.039) with renal impairment in Group A. The stage of chronic kidney disease (CKD) was estimated on the base of GFR (4v-MDRD).
ps0.013), and depended on several factors (kidney and liver
function, concurrently used drugs, hypoalbuminemia). MPA
levels were below the therapeutic range in 40% of the
patients in Group A and in 45% of the patients in Group B.
Mean MPA was 1.9"1.56 (SD) mg/L in Group A (target
C0)1.3 mg/L) and 2.4"1.69 mg/L in Group B (target
C0)1.9 mg/L). In Group C average value of MPA was
1.78"0.5 (SD) mg/L coadministered with everolimus (ns5)
and MPA was 3.6"2.5 (SD) mg/L in patients treated with
sirolimus (ns12). The mean values of cyclosporine C2
(598"174 mg/L), tacrolimus (6.8"2.92 mg/L) and evero-
limus (5.6"3.7 mg/L) were in the therapeutic range; the only
exception was sirolimus (3.7"2.4 mg/L), which was under
the therapeutic range (5–10 mg/L).
MPA levels of patients treated with a cyclosporine-MPA
combination were different at various stages of CKD. In
Group A trough level of MPA significantly increased (Krus-
kal-Wallis test: ps0.012), while peak level of cyclosporine
decreased (ANOVA: ps0.039) in more severe CKD stages
(Figure 2). In the case of renal function impairment cyclo-
sporine dose was lowered and MPA dose was raised to avoid
side-effects. Therefore, the MPA/cyclosporine ratio was sig-
nificantly higher at the stages of CKD3 and CKD4, com-
pared to CKD2 (Figure 3, Kruskal-Wallis test: ps0.015 and
0.04). Increasing MPA/cyclosporine ratio in more severe
stages of chronic renal disease was tolerable for the patients
and rejection could be avoided.
The dose adjusted according to the glomerular function
was tolerable for the patients and proved to be safe as no
kidney rejection was detected during the study.
Potential cytotoxic side-effects of immunosuppressive
drugs were also assessed by the WBC count and hemoglobin
level. Mean WBC count was 8.43"2.75 G/L in Group A and
8.68"2.89 G/L in Group B (reference range: 4.8–10.8 G/L),
slightly decreased WBC count was detected in 2% of these
patients. In Group C, WBC count was normal in all patients
with an average 7.60"1.73 G/L value. In Group A, CRP
was slightly elevated in 9% of the patients (3.8"4.8 mg/L)
and procalcitonin was in the reference range in 98% of the
patients (0.3"0.1 mg/L). Although individual hemoglobin
values compared to the sex-dependent reference ranges
(female: 120–160, male: 135–170 g/L) showed slight anemia
in 49% of the patients (128"21 g/L) in Group A, hemoglo-
bin or the number of red blood cells did not correlate with
MPA. So we concluded that mild anemia may be the con-
sequence of kidney disease and independent of the MMF
treatment. Although elevated urinary NAG index ()0.7
mmol/min/mmol) occurred in 79% of patients in Group A,
which indicated tubular damage, NAG indices did not cor-
relate with MPA levels. We suppose that other factors may
contribute to the tubular damage (complication of transplan-
tation, side-effects of concurrently applied immunosuppres-
sive drugs).
Discussion
On completion of kidney transplantation there are strict clin-
ical regimens for immunosuppressive therapy. When the
combined dosage of drugs is established or modified, the
first aim is to avoid kidney rejection and to minimize kidney
damage. MPA blood level depends on the dosage of the used
co-drug that can modify the enterohepatic recirculation of
MPA. Cyclosporine inhibits the recirculation of MPA, with
the starting dose of 2=1.5 g/day the target MPA value is
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Figure 3 Ratio of MPA trough level/cyclosporine peak level in
Group A.
Ratio of MPA trough level/cyclosporine peak level (units: mg/L for
both) was significantly higher at the stages of CKD3 and CKD4
compared to CKD2 in Group A (Kruskal-Wallis test: ps0.015 and
0.04).
C0)1.3 mg/L. As tacrolimus does not inhibit the recircula-
tion of MPA (8) with the starting dose of 2=1 g/day the
target value is higher, C0)1.9 mg/L. Our results were in
agreement with these requirements, the mean MPA level was
lower in Group A (1.9 mg/L) than in Group B (2.4 mg/L).
Although the mean MPA concentration (1.9 mg/L) was
above the target value (1.3 mg/L) in Group A, 40% of the
patients had MPA levels lower than required. The increase
in MPA level and the decrease in cyclosporine with the pro-
gression of renal impairment can be the consequence of both
the dosage adjustment according to CKD stages and the
change in the renal elimination, as MPA is excreted mainly
by the kidneys. The individual variations in MPA levels may
be connected to the renal and liver function, body mass and
genetic polymorphisms in the enzymes and other proteins
responsible for drug metabolism and transport (16, 17). Since
2008, TDM of MPA is not suggested as a routine test after
renal transplantation (8, 18, 19). The considerable individual
variance in blood level observed in this study underlines the
fact that MPA level depends on several factors. Our results
suggest that the applied doses for immunosuppression were
safe. Dosage adjustment according to the kidney function can
be characterized by the ratio of MPA trough level/cyclo-
sporine peak level. When the ratio increased from 1.53 (stage
CKD 2, median value) to 3.48 (stage CKD 4), kidney rejec-
tion could still be prevented and the therapy was more tol-
erable because of the decrease in gastrointestinal and
hematological side-effects. Although we observed a slight
correlation between the dosage and MPA level, the wide
range of blood levels necessitates individual therapy, taking
kidney function and the patient’s general clinical state into
consideration (20). As a long-term strategy, side-effects and
cost minimization should be evaluated together with the
actual kidney function.
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